Moderna has failed in its bid to secure an mRNA vaccine patent, but an IP Australia delegate gave the US biotech another shot at its application.
A judge has denied Austin Engineering’s bid for a $210,000 freezing order against a former sales representative, with a judge finding there was an arguable claim for breach of confidence but no evidence of a claim to more than nominal damages.
Apple has defeated a claim by an Australian non-practicing entity that its patents for a remote entry system were infringed by the tech company’s Touch ID and Face ID technology.
Sandoz has accused Amgen of ‘dragging the chain’ as the Swiss biotech continues to mull whether to launch infringement proceedings over six patents for its Prolia and Xgeve bone disease biologics.
IP Australia has rejected two patents by online graphic design company Canva, with a delegate dismissing the company’s argument the computer-implemented patent applications claim a manner of manufacture.
Generic drug maker Sandoz wants to shield information turned up by preliminary discovery orders from the eyes of Amgen patent attorneys in a spat over cheap versions of Amgen’s bone disease drugs, and says if they view the material they should be barred from prosecuting future related patents.
Famed restaurant chain Momofuku has lost its challenge to the ‘Momofuku’ word mark of instant noodle giant Nissin, with IP Australia finding consumers were not likely to be deceived or confused because of the different goods and services provided by the two companies.
Dairy company Fonterra is reportedly challenging a court’s refusal to give it certainty over lucrative licence agreements with Bega Cheese as it pursues a sale of its Australian business.
Biopharmaceutical company Amgen has lodged proceedings against generic maker Sandoz, calling for documents related to regulatory approval of a generic version of its top-selling bone disease treatments.
A company that manufactures vehicle sensing technology used to monitor public parking has been allowed more time to renew its patents, despite opposition from rival SARB.